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ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a relatively rare but fatal neurodegenerative disease 
characterized by progressive muscle paralysis, due to loss of upper and lower motor neurons. 
Signs of neuroinflammation have been reported in ALS, however it is still unknown whether 
neuroinflammation is a cause or a consequence of the motor neuron dysfunction. 
Neuroinflammation may also be one of the mechanisms underlying the overlap between ALS 
and other neurological, neuromuscular, and psychiatric disorders. Among neuromuscular 
disorders, the most studied disorder in association with ALS is multiple sclerosis (MS). MS is 
a complex disease of the central nervous system (CNS) characterized by chronic inflammation, 
demyelination, and neurodegeneration. A link between MS and psychiatric disorders has also 
been proposed. In this thesis we explored the associations of different correlates of 
neuroinflammation, including physical and cognitive fitness in early life (Study I), 
neurodegenerative and psychiatric disorders (Study II), neuromuscular diseases (Study III), 
depression and antidepressants use (Study IV) with the risks of either ALS or MS.  
In Study I, we investigated the association between physical and cognitive fitness in young 
adulthood with future risk of ALS. The study population included 1,838,376 Swedish men aged 
17-20. Information on physical fitness, body mass index (BMI), intelligence quotient (IQ), and 
stress resilience was retrieved from the Swedish Conscription Register between 1968 and 2010. 
Information on subsequent ALS diagnosis was retrieved from the Swedish Patient Register. 
There were 439 incident cases of ALS during follow-up. Higher physical fitness was associated 
with an increased risk of ALS before age 45, while higher BMI tended to be associated with a 
lower risk of ALS at all ages. Higher IQ was associated with an increased risk of ALS at age 
56 and onwards, whereas higher stress resilience was associated with a lower risk of ALS at 
age 55 and earlier. These results indicate that physical fitness, BMI, IQ, and stress resilience in 
young adulthood are associated with the development of early onset ALS.  
In Study II, we examined the risk of neurodegenerative and psychiatric disorders among 
individuals with ALS, compared to individuals free of the disease. The study population 
included 3,648 individuals with ALS and 36,480 age-, sex-, and county-of-birth-matched 
controls from the general population. In addition, we estimated the risk of neurodegenerative 
and psychiatric diseases among the relatives of ALS patients, compared to the relatives of the 
controls, to assess the potential contribution of familial factors. Individuals with previous 
neurodegenerative or psychiatric diseases had an increased risk of ALS, compared to 
individuals who did not have these diseases. After diagnosis, ALS patients had increased risks 
of neurodegenerative or psychiatric diseases, compared to individuals free of ALS. First-degree 
relatives of individuals with ALS had higher risk of neurodegenerative diseases compared to 
relatives of controls. Children of ALS patients had higher risk of psychiatric disorders, 
compared to children of controls. The increased risk of neurodegenerative disorders among 
relatives of ALS patients may be attributable to the overlapping etiopathogenesis of different 
neurodegenerative diseases. The increased risk of psychiatric disorders among ALS patients 
  
 
and their children may be due to non-motor symptoms of ALS or a severe stress response after 
the diagnosis of ALS. 
In Study III, we aimed at validating the co-occurrence of ALS and other neuromuscular 
diseases, investigating the temporal relationship between the diagnoses and clinical 
characteristics of patients with both ALS and other neuromuscular diseases. Using information 
from the Swedish Patient Register, we identified all patients diagnosed with ALS in Sweden 
between 1991 and 2014, who had also a concurrent MS, myasthenia gravis (MG), 
inflammatory polyneuropathies (IP), or dermatopolymyositis (DMPM). The group included 
263 patients. We validated medical records for 92% of these patients to confirm the overlap. 
Then, we compared patients with a confirmed overlap (N=28) with an independent sample of 
patients with only ALS (N=271). Among the patients with a validated overlap, 12 had a 
confirmed diagnosis of MS, nine a confirmed diagnosis of MG, four a confirmed diagnosis of 
IP, and three a confirmed diagnosis of DMPM. Seventy-nine percent of the patients with a 
confirmed overlap had these diagnoses prior to ALS. Compared to patients with only ALS, 
patients with a confirmed overlap were older at symptoms onset, had higher prevalence of 
bulbar onset, but used riluzole and non-invasive ventilation less frequently. These results show 
that neuroinflammation around the motor unit might trigger ALS in a small subgroup of 
patients. 
In Study IV, we estimated the risk of depression and antidepressants prescription among 
patients with relapsing-remitting MS (RRMS) and explored the bi-directional relationship 
between different disease modulatory therapies (DMTs) and depression or antidepressants use. 
We included 4,867 patients with RRMS who were diagnosed in Sweden between January 2005 
and September 2018 and did not have a diagnosis of depression or antidepressants prescription 
before initiation of their first DMT. We compared the risk of depression (defined by diagnosis 
or antidepressants prescription) in relation to different DMTs, using interferons as the reference 
and examined DMT discontinuation or relapse in relation to depression. RRMS patients treated 
with rituximab had a decreased risk of depression, compared to patients treated with 
interferons. No differences were found for other DMTs examined (dimethyl fumarate, 
fingolimod, and natalizumab), compared to interferons. Depression was not associated with the 
risk of DMT discontinuation or MS relapse. These results provide evidence for a lower risk of 
depression among RRMS patients treated with rituximab, compared to interferons.  
In conclusion, results from the studies included in this thesis support the notion that 
neuroinflammation might precede the onset of ALS.  In addition, different neurodegenerative 
diseases might share common disease mechanisms including neuroinflammation. The reduced 
risk of depression in relation to treatment with rituximab among patients with RRMS also 
suggests that neuroinflammation might underlie the link between psychiatric disorders and 
neurodegenerative diseases because rituximab may modulate both the MS- and depression-
related inflammation.  
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1 INTRODUCTION 
The term “neuroinflammation” refers to the process that includes the inflammatory responses 
within the central nervous system (CNS). Neuroinflammation is a pathological component of 
several neurodegenerative diseases.  
Amyotrophic lateral sclerosis (ALS) is a relatively rare neurodegenerative disease, which 
usually has its onset between age 40 and 70. In ALS, a progressive loss of upper and lower 
motor neurons leads to paralysis and wasting of the muscles, causing progressive disability 
and, ultimately, death, often due to respiratory failure. Different signs of neuroinflammation 
have been observed in association with ALS, but the causal relationship between them remains 
unknown. Because neuroinflammation has been reported in association with other 
neurodegenerative diseases, and with neurological and psychiatric disorders generally, 
neuroinflammation may also be one of the mechanisms that explain the overlap between ALS 
and these diseases. Multiple sclerosis (MS) is the most studied neuromuscular disease in 
association with ALS.  
MS is a complex diseases of the CNS characterized by inflammation, demyelination, and 
neurodegeneration. In most patients, MS is diagnosed after the onset of clinical symptoms, 
which can be partially or totally reversible (relapsing-remitting MS, RRMS). There is however 
great variation in symptoms presentation and disease course. Currently, there is no available 
medication that can cure MS, but several treatment options are available to reduce symptoms 
severity and relapse frequency. Similar to ALS, the risk of psychiatric disorders has also been 
reported to be increased among MS patients.  
In this thesis, we explored the relationship between different correlates of neuroinflammation 
with the risks of ALS (Studies I, II, and III) and MS (Study IV). 
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2 ALS BACKGROUND 
2.1 ALS DISEASE CHARACHTERISTICS 
ALS is a relatively rare neurodegenerative disease. Individuals with this disease experience 
progressive loss of upper and lower motor neurons. The mean age of ALS onset is 65 years, 
with most people diagnosed between the ages of 40 and 701. Among the majority of patients, 
symptoms quickly progress into muscle paralysis and wasting, usually leading to progressive 
disability and death (commonly due to respiratory failure) within 1-3 years from diagnosis. 
Only around 10% of the patients clearly have a familial form of the disease and the vast 
majority appear as sporadic cases2.  
In a healthy individual, the upper motor neurons in the motor region of the cerebral cortex and 
the brain stem, send movement commands to the lower motor neurons, which project from the 
brainstem or spinal cord to the muscles. The muscles then contract, allowing voluntary 
movements of the body. In a patient with ALS, however, motor neuron degeneration interrupts 
the communication between the brain and the muscles, either at the upper motor neuron level 
or at the lower motor neuron level. Hence, the voluntary muscles no longer receive movement 
commands and atrophy as a consequence. The first symptoms of ALS are either a weakening 
of the extremities, so called spinal onset, or reduced capacities to speak and swallow, so called 
bulbar onset. Even though motor symptoms characterize ALS, cognitive and behavioral 
impairment affects up to 50% of ALS patients during the course of the disease. 
2.2 ALS CLINICAL PRESENTATION AND DIAGNOSIS 
In 1869, Jean-Martin Charcot, a French neurologist working in Paris, was able to identify ALS 
as a specific neurological disease with distinct pathology, and separated ALS from other 
disorders with similar symptoms3,4. Although the understanding of the disease has greatly 
evolved since then, due to epidemiological, molecular, and genetic discoveries, no definite test 
for the diagnosis of ALS is yet available, except for autopsy.  
In case of a limb onset (accounting for 60% of the cases), patients start noticing the first 
symptoms through asymmetric spasticity and weakness (signs of upper motor neuron 
dysfunction), or through fasciculation, cramps, and muscle wasting (signs of lower motor 
neuron dysfunction)5. In case of a bulbar onset (about 35% of the patients), patients experience 
the first symptoms as progressive difficulty in talking (dysarthria), difficulty in swallowing 
(dysphagia), or emotional liability5. Only a minority of patients (5%) experience respiratory 
problems as initial ALS symptoms5.  
Because of the lack of valid diagnostic biomarkers6, the diagnosis of ALS is made clinically 
based on the Revised El Escorial criteria, which require the evidence of lower or upper motor 
neuron degeneration as well as a progressive spread of signs or symptoms7. Revised El Escorial 
criteria categorize diagnostic certainty based on the burden of disease, according to the number 
of body regions showing signs of upper and lower motor neuron involvement. Clinicians then 
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classify the ALS diagnosis as definite, probable, or possible. The original version of the El 
Escorial criteria included a “suspected ALS” category, which would include patients showing 
signs of lower motor neurons involvement in two or more regions.  In 1998, this category was 
deleted from the Revised El Escorial criteria classification system to increase the specificity of 
the diagnosis. 
In addition to the Revised El Escorial criteria, clinicians must also rule out alternative 
diagnoses. The ALS diagnosis is more plausible if patients do not show electrophysiological 
or pathological evidence of other diseases characterized by lower or upper motor neuron 
degeneration, or neuroimaging evidence of diseases that could lead to specific clinical and 
electrophysiological signs7. As a result, patients have to go through a stressful diagnostic 
procedure, which takes on average one year to complete from the first symptoms onset8. 
2.3 ALS ETIOPATHOLOGY 
The etiology of ALS, especially sporadic ALS, likely involves a complex interplay among 
genetics, environmental exposures, and lifestyle factors. Although the knowledge about ALS 
pathophysiology is still growing, the neuropathological distinctive characteristic of the disease 
are ubiquitinated proteinaceous inclusions in motor neurons5. The main constituent of these 
inclusions varies depending on specific ALS subtypes, but almost all ALS patients show 
features of a TAR deoxyribonucleic acid-binding protein 43 (TDP43)-associated 
proteinopathy9. Other protein aggregates that might be found are neurofilamentous hyaline 
congrolomerate, misfolded superoxide dismutase 1 (SOD1), and TDP43-negative inclusions5. 
Additional mechanisms involved in the disease are impaired protein homeostasis, oxidative 
stress, impaired deoxyribonucleic acid (DNA) repair, mitochondrial dysfunction, dysregulated 
vehicle transport, and aberrant ribonucleic acid (RNA) metabolism5. All these mechanisms 
seem to be interlinked and probably depend on the initial cause of the disease5. 
2.4 ALS TREATMENT 
To date, there is no curative treatment for ALS. Instead, treatments are mainly tailored to slow 
disease progression and manage symptoms. Since 1995, the only drug approved by the United 
States Food and Drug Administration (FDA) to alter ALS progression has been riluzole, which 
prolongs the survival of ALS patients by an average of 2-3 months. Riluzole reduces the release 
of glutamate, the excess of which might destruct the nerve cells10. However, only older patients 
with bulbar onset seem to experience a slightly increased survival, whereas younger patients 
with limb onset are less likely to benefit from riluzole11. Additionally, riluzole must be 
administered in the early stages of the disease to be beneficial, as the glutamatergic action of 
riluzole depends on viable motor neuron activity12.  
More recently, the antioxidant drug edaravone was approved in Japan (2015) and in the United 
States of America (2017) to treat ALS. However, this drug seems to work only for patients with 
early age onset and rapidly progressing disease. Originally developed for the treatment of 
stroke, edaravone is a free radical scavenger administered intravenously. Although the 
mechanism of edaravone in ALS is unknown, it is thought to mitigate oxidative injury in the 
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motor neurons of the CNS at risk for degeneration by eliminating lipid peroxides and hydroxyl 
radicals13. Given the unclear effect on muscle strength, respiratory function, and quality of life, 
as well as the costly and labor-intensive nature of the treatment, the European Medicines 
Agency has not approved this drug and several countries exclude it from their health care 
systems5,14.  
Given the lack of a curative treatment, clinical guidelines encourage early access to 
symptomatic treatment, that is, palliative treatment15. Clinical guidelines also encourage early 
non-invasive ventilation, to improve the prognosis of ALS patients by compensating for 
weakness of the respiratory muscles16. Patients presenting with dysphagia (difficulty in 
swallowing) have the option to receive nutritional support by gastrostomy feeding16.  
Overall, the optimal management of ALS patients requires access to a multidisciplinary team 
that is flexible and responsive to the evolving nature of the condition17. The benefit of having 
access to a range of healthcare professionals was shown by research highlighting the longer 
survival of ALS patients attending multidisciplinary clinics18. 
2.5 ALS EPIDEMIOLOGY 
2.5.1 Incidence and prevalence 
The incidence of ALS, estimated from population-based studies in Europe, is about 2-4 cases 
per 100,000 individuals per year19-22. The incidence of ALS seems to differ based on ancestral 
original, with lower incidence recently reported in Beijing, China23 (0.8 cases per 100,000 
individuals per year) and South Korea24 (1.2 cases per 100,000 individuals per year). Overall, 
the incidence seems to be higher among men than women, with a male/female ratio between 1 
and 325, possibly due to a higher incidence of spinal onset ALS among males1. The incidence 
of ALS has been reported to increase during the recent decades from multiple countries across 
the world21,22,26-29. This might reflect a real increase of ALS incidence or result from improved 
diagnostics, reporting, or survival rate of competitive diseases30-32. Although the incidence 
appears to be increasing, given the fast disease progression, prevalence of ALS remains quite 
low, and was estimated at 4.1-8.4 cases per 100,000 individuals in recent population-based 
studies19-22,24,29,33-36. 
2.5.2 Risk factors 
Historically, the established risk factors for ALS have been older age, male sex, and family 
history. Genetic studies have identified several important genes responsible for an increasing 
proportion of familial ALS cases, including chromosome 9 open reading frame 72 (C9orf72), 
SOD1, TDP43, and fused in sarcoma (FUS)37. However, given that more than 90% of ALS 
patients have no clear family history, the overall contribution of single genes to ALS etiology 
still appears weak38. Instead, researchers speculate that an interaction between genetic and non-
genetic factors contributes to the etiology of ALS39. 
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Various hypotheses, including defects in energy metabolism, chronic neuroinflammation, 
heavy metal exposure, strenuous physical exercise, etc., have been proposed as casual factors 
leading to ALS. However, it is hard to draw definitive conclusions about these factors because 
our knowledge of ALS pathophysiology is still developing and past studies might suffer from 
methodological problems. More recently, Mendelian randomization studies have suggested a 
causal relationship between ALS and physical activity, smoking, blood lipid levels, and 
education40,41.  
2.5.3 Prognostic factors 
In ALS patients, death due to respiratory failure usually occurs within 1-3 years from diagnosis. 
Only about 10% of ALS patients present with a slower diseases progression leading to a 
survival of 10 years or more after diagnosis. Healthcare professionals usually measure the 
progression of ALS with the revised version of the ALS functional rating scale (ALSFRS-R)42. 
This scale monitors the progression of the patient disability by investigating four domains 
consisting of gross and fine motor tasks, bulbar functions, and respiratory function (added in 
the revised version of the scale)42. Reasons for a slower disease progression are unknown, 
although prognostic factors such as spinal onset, male sex, lack of cognitive dysfunction, longer 
diagnostic delay, and younger age at diagnosis have been associated with better survival rate43. 
2.6 NEUROINFLAMMATION IN ALS 
“Neuroinflammation” is a term that refers to the inflammatory responses within the CNS that 
commonly accompany neurodegeneration. Signs of neuroinflammation are present in human 
post-mortem samples from ALS patients44. Additionally, key cellular modulators of 
neuroinflammation, such as astrocytes, microglia and immune cells, are correlated with ALS 
pathogenesis45. Although there is an association between signs of neuroinflammation and ALS, 
it is under debate whether neuroinflammation is a cause or consequence of motor neuron 
dysfunction in ALS45. One hypothesis is that systemic immune activation might play a role in 
neuroinflammation. However, studies that focus on inflammatory conditions around the motor 
unit might hold promise, because axons, dendrites, and synapses show the first pathological 
changes associated with ALS46. The hypothesis of a causal relationship between chronic 
inflammatory status in close proximity to the motor neuron unit and motor neuron degeneration 
is biologically plausible. For example, a normal axonal transport is indispensable for motor 
neurons46. Because axons may be up to 20,000 times larger in size than the neuronal cell body 
and extend up to one meter, axons are highly fragile morphologically and in terms of 
functionality46, and could be damaged by increased level of neuroinflammation.  
Several factors could contribute to the increased level of neuroinflammation among patients 
with ALS. For example, an association between intense physical activity and ALS has been 
proposed since long47-54.  In addition to the recently reported shared genetic predisposition to 
physical activity and ALS40, this association could possibly also be explained by the increased 
inflammatory status in proximity to the muscles and tendons among people who have a history 
of engaging in intense physical activity55.   
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2.7 ALS COMORBIDITIES 
ALS seems to overlap with other neurological diseases and psychiatric disorders. 
Neuroinflammation might be one of the possible explanations for this overlap. I speculate 
below on how neuroinflammation might be one of the reasons why ALS could be comorbid 
with a host of other neurological and psychiatric conditions.   
2.7.1 Neuromuscular diseases 
During the advanced stages of ALS, the diagnosis can be ascertained with a high degree of 
confidence, whereas in the early stages of the disease, symptoms of ALS are not specific but 
rather common to other neuromuscular diseases. As a result, ALS patients might be initially 
misdiagnosed with other neuromuscular diseases characterized by neuroinflammation in 
different sites, such as MS (inflammation in the CNS), myasthenia gravis (MG, inflammation 
in the neuromuscular junction), inflammatory polyneuropathies (IP, inflammation in the 
peripheral nervous system), and dermatopolymyositis (DMPM, inflammation in the muscles 
and skin). Although early symptoms of ALS may mimic MS, MG, IP, and DMPM56, making 
diagnostic uncertainty an attractive explanation for any concurrence between these diseases, 
biological overlap among these diseases probably also exists57. Consequently, a higher-than-
expected concurrence of ALS and neuromuscular diseases might be attributed to diagnostic 
uncertainty, real biological overlap, or perhaps both. Although a common genetic etiology 
might contribute to the biological overlap, it is also possible that chronic inflammation is in the 
causal pathway to neurodegeneration, as discussed above.  
ALS has been studied in conjunction with other neuromuscular diseases, primarily MS, which 
is an autoimmune diseases characterized by inflammation in the CNS. This research interest 
started with case reports of concurrence58-62. Given the suspicion of an overlap between ALS 
and MS, researchers studied five patients from the United Kingdom with concurrent ALS/MS 
and identified the GGGGCC hexanucleotide repeat expansion of C9orf72, a polymorphism 
found in a significant proportion of both sporadic and familial ALS patients57. In addition to 
case reports, larger epidemiological studies also investigated the ALS/MS concurrence and 
found an association between MS and later ALS onset63, as well as an increased risk for MS 
among children of ALS patients64. In Sweden, a high correlation between mortality rates of 
ALS and MS was observed between 1952 and 199265, but a more recent study did not confirm 
the correlation66.  
Similar to MS, researchers have also found overlap between ALS and MG67-70. MG is a disease 
of neuromuscular transmission in which autoantibodies bind to the neuromuscular junction. 
The aforementioned cohort study that investigated the risk of ALS in patients with MS, also 
found that MG was associated with later ALS risk; similar result was also reported for 
polymyositis but not dermatomyositis63. Polymyositis is a disease characterized by chronic 
inflammation of the muscles71 and has recognized common pathological features with ALS. 
Despite these shared pathological features, the association between polymyositis and ALS has 
only been investigated in one other sample71.  
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In contrast to the aforementioned neuromuscular diseases, the overlap between IP and ALS has 
not yet been systemically investigated. Given the similarity between the initial symptoms of 
ALS and IP, research has mainly focused on techniques aiming to aid a differential diagnosis 
between these diseases, particularly with Guillain-Barré syndrome (GBS)72. GBS is a form of 
IP, presenting with muscle weakness as a result of damage in the peripheral nervous system. 
2.7.2 Neurodegenerative diseases 
Clinical and pathologic overlaps between ALS and other neurodegenerative diseases have been 
demonstrated2,73 and neuroinflammation is an acknowledged pathological component of 
numerous neurodegenerative diseases74. Specifically, 30-50% of ALS patients demonstrate 
cognitive impairment75 and 5-10% of ALS patients fulfill criteria for frontotemporal dementia 
(FTD)76. Few studies, however, have estimated the risk of other neurodegenerative diseases 
among patients with ALS, probably due to the rareness of ALS and, subsequently, of its 
concurrence with other neurodegenerative diseases77. A German study found a higher 
prevalence of dementia and Parkinson's disease (PD) among ALS patients, compared to the 
general population77. A Swedish register-based study found an association of ALS with a 
higher subsequent PD risk78. Increased risks of PD and dementia have also been found among 
relatives of ALS patients79, which suggests that there might be a partly shared etiopathogenesis 
between different neurodegenerative diseases79-81.  
In the familial forms of different neurodegenerative disorders, the persistent presence of a 
precipitating factor might help to sustain the observed inflammatory reaction82. The 
precipitating factor might be the disease-causing mutant protein in the familial dominant forms 
(for example, amyloid β1–42 for Alzheimer's disease, AD, mutant α-synuclein for PD, and 
SOD1 for ALS). With the initial aim of combating the precipitating factor, the inflammatory 
reaction ends up turning into a harmful process that contributes to further neuronal damage82. 
2.7.3 Psychiatric disorders 
Patients with neurodegenerative diseases might also have higher-than-expected comorbidity 
with psychiatric disorders83. A growing body of evidence suggests that many psychiatric 
disorders, including stress-related disorders, depression, bipolar disorder, and schizophrenia, 
are associated with distinct inflammatory responses in the periphery and CNS84,85. Thus, it is 
possible that the inflammatory response from microglial activation can contribute to brain 
pathology. In contrast to this hypothesis, an earlier study suggested that the psychological 
distress associated with receiving and adjusting to an ALS diagnosis might represent another 
underlying reason for psychiatric comorbidity in ALS86. 
Patients with ALS were shown to have increased risk of psychiatric disorders in some but not 
all studies87-89 and we know little about the risk of psychiatric disorders among families of ALS 
patients79. Specifically, previous research has reported an overlap between ALS and psychosis 
among patients with ALS-FTD90, and ALS patients and their relatives were reported to have 
an increased risk of schizophrenia and psychotic illness79,88. A recent population-based study 
further identified a clustering of neuropsychiatric disorders among relatives of ALS patients, 
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suggesting the presence of a common genetic basis between ALS and psychiatric disorders in 
the Irish population91. Our group reported that ALS patients had increased risk of depression 
and antidepressants use compared to controls, especially shortly before and after diagnosis89. 
Furthermore, individuals with abusive alcohol consumption were reported to have a reduced 
risk of ALS92, whereas individuals with abusive use of opioids were reported to have a higher 
risk of ALS93. 
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3 MS BACKGROUND 
3.1 MS DISEASES CHARACTERISTICS 
MS is the most prevalent chronic inflammatory disease affecting the CNS94. It is characterized 
by attacks of the immune system on myelin, which is a protective layer of fatty white substance 
that surrounds the axon of some nerve cells. This damage can cause a lack of communication 
within the brain and between the brain and the body by leading to a slower impulse 
transmission. The extent and severity of symptoms greatly vary among patients, depending on 
which and how many nerve cells are affected. Most patients receive diagnosis of MS between 
the ages of 20 and 40 years95. 
3.2 MS CLINICAL PRESENTATION AND DIAGNOSIS 
MS was first described in 1868 by Jean-Martin Charcot, the same French neurologist that firstly 
distinguished ALS from other neurological diseases. Based on observations of MS pathological 
and clinical features, he defined the first three diagnostic criteria of MS: involuntary eye 
movement (nystagmus), lack of muscle control and coordination (ataxia), and difficulty in 
talking (dysarthria)96.  
Typically, MS initially manifests as blurred vision, sensory disturbance (such as tingling or 
loss of sensation), and motor impairment97. Subsequently, long periods of remission can 
follow, alternated by successive attacks with new symptoms or relapses. In the initial phases 
of MS, the symptoms can partially or completely regress. In the later phases, symptoms 
progress leads to a loss of ability to walk independently. 
Giving an MS diagnosis is a challenging process, given the radiologic and clinical 
heterogeneity of the disease94,98. Currently, no externally validated blood immune marker has 
adequate sensitivity and specificity to be used for the diagnosis of MS, which probably reflects 
the genetic and environmental heterogeneity of the disease94. The diagnosis is therefore made 
clinically, according to the 2017 revised McDonald criteria99 with the aid of imaging scans 
such as magnetic resonance imaging (MRI) and analysis of cerebrospinal fluid.  
3.2.1 Phenotypic classification 
In 1996, the phenotypic classification of MS was defined by members of the international MS 
community in four different groups: RRMS, primary-progressive MS (PPMS), secondary-
progressive MS (SPMS), and progressive-relapsing MS (PRMS)100. Following a greater 
understanding of the clinical course of MS as well as its pathology, the clinical course of MS 
was re-defined in 2013101. The new classification system retained the RRMS, PPMS, and 
SPMS with some modifications, whereas the PRMS was removed and is now categorized as 
“active PPMS” 101.  
RRMS is the most common phenotypic presentation of MS including around 85% of MS 
patients. RRMS is characterized by relapses that may or may not leave permanent deficits, with 
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no new symptoms occurring in between periods of remission. Over time, most RRMS patients 
convert to SPMS, a stage of progressive deterioration without periods of remissions or relapses. 
A minority of patients, PPMS, do not have any initial periods of remission or relapses and show 
from start progressive deteriorations. 
3.3 MS ETIOPATHOLOGY 
Despite the etiology of MS is still unclear, a mix of environmental and genetic factors seem to 
underlie its pathogenesis. Immunological, genetic, and histopathology studies indicate that 
autoimmunity appears to play a major role in MS pathogenesis102. However, MS is also 
considered a neurodegenerative condition103.  
Although most MS lesions can appear throughout the CNS, they are most easily identified in 
the white matter as focal areas of demyelination, inflammation, and glial reaction94. In some 
cases, lesions can reverse; however it is not well understood if the myelin sheet is reformed or 
if the inflammation is resolved94. Demyelination can also occur in gray matter104-106. It is also 
possible to observe loss of retinal ganglion cells adjoining the optic nerve107 and retinal 
damage108.  
3.4 MS TREATMENT 
Currently, there is no curative treatment for MS94. However, in contrast to ALS, several 
treatments are approved by the FDA to lower inflammatory disease activity and reduce the 
frequency of attacks in RRMS and development of new lesions in the white-matter. 
These disease modulatory therapies (DMTs) include different interferon beta and glatiramer 
acetate preparations, monoclonal antibodies (natalizumab, alemtuzumab, daclizumab, and 
ocrelizumab), orally administered small-molecule agents (fingolimod, dimethyl fumarate, and 
teriflunomide), a chemotherapeutic agent (mitoxantrone), and hematopoietic stem cell 
transplantation. In Sweden, rituximab, a DMT approved for rheumatoid arthritis but not MS, 
has gained popularity and became the most widely used DMT for RRMS. Its popularity derives 
from a series of real-world studies showing that rituximab outperforms regular DMTs109. Other 
treatments commonly given for managing signs and symptoms of MS include muscle relaxants 
to treat muscle spasms, medications to treat fatigue, and dalfampridine to increase walking 
speed.  
3.5 MS EPIDEMIOLOGY 
3.5.1 Incidence and prevalence 
Globally, the incidence of MS is about 2.5 cases per 100,000 individuals per year. However, 
the incidence rate is higher in Europe with 3.8 cases per 100,000 person-years, compared to 
only 1.5 cases per 100,000 person-years in America110. In Africa, the incidence is as low as 0.1 
per 100,000 person-years. Although there is a hypothesis that risk for MS co-occurs with colder 
weather, the low incidence rate in Africa might be at least partly attributable to a lack of 
diagnostic tools (e.g., MRI scanners)111. Studies indicate that the incidence rates have more 
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than doubled in the past decade, perhaps due to improved diagnostics112. Because of the long 
survival time, the prevalence of MS is higher than the incidence, and is estimated as 30 cases 
per 100,000 individuals110. The prevalence is higher in North America, Europe, and Australia 
(over 60 cases per 100,000), and lower in South America and South East Asia (less than 20 
cases per 100,000)110. 
3.5.2 Risk factors 
It remains unknown if MS is caused by only one or multiple factors. However, because it is 
difficult to identify a common etiologic trigger behind all MS cases, it seems more plausible 
that a wide range of genetic and environmental factors contribute to the disease94. Several risk 
factors related to the development of inflammatory and demyelinating lesions with 
heterogeneous axonal loss have been identified, including Epstein-Barr virus and 
mononucleosis, risk genes, temperate latitude (reflecting sunlight exposure and consequently 
vitamin D levels but also possibly a genetic contribution), fibrinogen, toxins, trauma, low 
vitamin D, smoking, and obesity94. Furthermore, for unknown reasons, women are affected by 
MS twice as often as men, as commonly seen in other autoimmune diseases94.  
3.5.3 Prognostic factors 
The median survival of MS patients is 40.6 years from disease onset, leading to a shortened 
life expectancy of seven years compared to the general population113. Factors associated with 
slower disease progression include lower grade of inflammation, fewer spinal cord lesions, 
endogenous repairs, preserved axons and synapses, earlier treatment, and younger age94.  
3.6 MS AND DEPRESSION 
Already at diagnosis, the quality of life of RRMS patients is impacted by the presence of 
depression114,115. Severe depressive symptoms occur in 19-40% of MS patients116-123, double 
that of the general population124. In Sweden, MS patients of working age had a higher risk of 
depression and selective serotonin reuptake inhibitors (SSRIs) prescription compared to 
individuals without MS125. Moreover, MS patients have an elevated risk of suicide126,127, 
particularly during the year immediately after MS diagnosis128. This seems to suggest that 
receiving such diagnosis might be highly stressful for MS patients. However, there is evidence 
that the depression-MS association is bidirectional because depression has been suggested to 
predict later MS129, and such result pattern could not be attributed to shared genetics alone129. 
One speculation is that inflammation in the CNS is the common denominator behind both 
depression and MS130. 
DMTs of MS appear to also have an influence on depressive symptoms. Given that depression 
co-occurs frequently with MS, and that DMTs might modify the probability of depression, it 
might be fruitful to investigate the occurrence of depression in context of different DMTs in 
RRMS. To date, however, there have been few such investigations. A limited number of studies 
indicate that fingolimod and natalizumab improve depressive symptoms in MS patients131-135. 
In contrast, other DMTs appear to worsen depressive symptoms, in particular interferon beta-
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1b136,137, which has been shown to be associated with an elevated risk of suicide in early 
trials138,139. However, the association between interferon beta-1b and suicide as reported in the 
early trials was later shown to be explained by a prior history of psychiatric disorders140, and 
failed to replicate in later larger studies120,141,142. Nevertheless, all DMTs, and not just interferon 
beta-1b, have depression listed as a possible side effect133. 
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4 THESIS HYPOTHESES AND STUDY AIMS 
ALS shows signs of neuroinflammation44,45. However, due to a lack of large prospective 
epidemiological studies, the directionality of the association between neuroinflammation and 
ALS remains unclear (i.e. if neuroinflammation precedes or follows the onset of ALS). We 
hypothesized that neuroinflammation around the motor unit precedes the onset of ALS.  
Several factors could contribute to the increased level of neuroinflammation among patients 
with ALS. We hypothesized that high levels of physical activity might be one of them, due the 
observed association between intense physical activity and inflammatory status in proximity to 
the muscles and tendons, joints, and peripheral nerves55.  
It has also been observed that ALS seems to overlap with other neurodegenerative2,73,76-78, 
neuromuscular57,58,63,67-71, and psychiatric diseases87-89,91-93,143, all of which are associated with 
neuroinflammation in different body regions. We therefore hypothesized that 
neuroinflammation might be one of the possible explanations for such overlap.  
MS is a neuromuscular diseases characterized by neuroinflammation in the CNS74 and has been 
shown to overlap with ALS57,58. As in ALS88,89, depression is a common comorbidity of MS 
patients129. The observation that this comorbidity in MS is not explained by genetic liability129 
implies that the etiology of depression in MS is multifactorial and might include a mix of 
psychological and biological factors, including neuroinflammation124,144. We hypothesized that 
treatment of MS might bring additional benefits, apart from symptomatic relief, by modulating 
the MS-associated inflammatory responses and thereby the risk of depression142,145. 
 
Figure 1. Schematic representation of the thesis hypotheses.   
 
To test these hypotheses, we conducted two studies to investigate the associations of 
inflammation in different tissues in close vicinity to motor neurons, namely, muscles and 
tendons (associated with intense physical activity), muscles and skin (DMPM), neuromuscular 
junction (MG), peripheral nervous system (inflammatory polyneuropathies, IP), and CNS 
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(MS), with the risk of ALS (Studies I and III). We conducted two additional studies to assess 
the relationship between neuroinflammation, psychiatric disorders, and neurodegeneration in 
both ALS and MS (Studies II and IV).  
We specifically aimed to: 
• Explore whether physical and cognitive fitness at age 17-20 predicts the risk of ALS in 
adulthood (Study I) 
 
• Estimate the risk of neurodegenerative and psychiatric diseases among patients with 
ALS and their relatives (Study II) 
 
• Validate the concurrence of ALS and neuromuscular diseases MS, MG, IP, and 
DMPM; investigate the temporal relationship between the diagnoses among patients 
with a confirmed overlap; and investigate if the clinical characteristics of the concurrent 
patients are different compared to patients with only ALS (Study III) 
 
• Estimate the risk of depression and antidepressant prescription in relation to different 
MS DMTs, and investigate if depression or antidepressants prescription affects DMT 
discontinuation or MS relapse (Study IV) 
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5 DATA SOURCES 
We used population-based data from different sources: several Swedish National Registers146-
151, medical records review, and the Swedish MS Registry152. We cross-linked all the registers 
by using a unique identifier derived from the personal identity number, which is assigned at 
birth or at immigration to any person resident in Sweden for at least one year153.  
5.1 SWEDISH NATIONAL REGISTERS 
Epidemiological research in Sweden owes its success to the long-standing tradition of 
maintaining population-based records of clinical and demographic information in national 
registers154. An overview of the Swedish National Registers is presented in Table 1.  
The Total Population Register collects information on sex, and date and place of birth on all 
individuals that were resident in Sweden since 1968, when the register was established147. 
The Migration Register147 and the Causes of Death Register148 collect information on 
migration (in and out of Sweden) since 1968 and date and causes of death since 1961, 
respectively.  
The Population and Housing Censuses have been conducted every five years between 1960-
1990 and include socioeconomic information such as type of employment, household 
composition, and type of accommodation.  
The Swedish Multi-Generation Register connects each individual born in Sweden since 
1932, and alive from 1961 onward, to his/her biological parents148. In case of adoption, each 
individual is also linked to the adoptive parents. 
The Swedish Patient Register collects hospital records data in Sweden since 1964 and has 
nationwide coverage since 1987146. Since 2001, it covers hospital-based outpatient specialist 
care. Diagnoses given at each hospital visit are classified according to the Swedish Revisions 
of the International Classification of Disease (ICD) codes (ICD-7 before 1969, ICD-8 during 
1969-1986, ICD-9 during 1987-1996, and ICD-10 from 1997).  
The Swedish Prescribed Drug Register was established in July 2005 and includes 
information on all prescribed medications in Sweden151 classified according to the Anatomical 
Therapeutic Chemical (ATC) system. Compared to the other national Swedish registers, the 
Prescribed Drug Register was established relatively late because of confidentiality concerns. It 
includes information such as substance of the dispended item, dosage, date of prescription, and 
date of dispense. A limitation of this register is that it does not include over-the-counter 
medications, vaccines, and drugs dispensed at hospitals or nursing homes151.  
The Swedish Conscript Register includes all males who underwent conscription examination 
in Sweden during 1968-2010. Attending conscription examination was mandatory for all males 
when they turned 18 years old, only those with severe physical or mental disabilities were 
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exempt. During examination, trained healthcare professionals collected several parameters of 
physical and cognitive fitness to establish which individuals were fit for military service. 
Females attending conscription examination were also included in this register since 1975, 
when females were allowed in Sweden to serve in the military. However, given that female 
attendance to conscription examination was voluntary, the register has national coverage 
during 1968-2010 only on males. In 2018, mandatory conscription examination was once again 
implemented, this time in a gender-neutral fashion155.  
 
Table 1. Overview of the Swedish national registers used in the constituent studies of this thesis. 
Register Date of 
establishment 
Date of national 
coverage 
Information 
extracted 
Used in 
Causes of Death 
Register 
1961 1961 Date of death Studies I, II, 
and IV 
Conscript Register 1968 1968-2010 for males Physical and 
cognitive fitness 
assessed at military 
conscription 
examination 
Study I 
Migration 
Register 
1968 1968 Date of migration to 
Sweden or emigration 
from Sweden 
Studies I, II, 
and IV 
Multi-Generation 
Register 
1968 1968 Familial link for all 
individuals born in 
Sweden since 1932 
Studies I and II 
Patient Register 1964 1987 for inpatient care 
2001 for outpatient 
care 
Inpatient and 
outpatient admissions 
and discharges 
records 
Studies I-IV 
Population and 
Housing Censuses 
1960 1960-1990 Socioeconomic status Study I 
Prescribed Drug 
Register 
July 2005 July 2005 Dispensed prescribed 
drugs 
Study IV 
Total Population 
Register 
1968 1968 Sex, date, and 
country of birth of 
Swedish residents 
Studies I, II, 
and IV 
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5.2 MEDICAL RECORDS REVIEW 
Population-based registers offer the opportunity to conduct unbiased investigations on several 
medical conditions affecting the entire Swedish population. However, national registers lack 
disease-specific information about the clinical course, as well as laboratory results and detailed 
phenotypic information. We therefore conducted a medical records review of validated ALS 
patients with concurrent neuromuscular diseases in order to obtain detailed information on age 
at disease onset, site of onset, disease progression profile, and cognitive impairment among this 
group of patients. 
5.3 THE SWEDISH MS REGISTRY 
In Study IV, we used information from the Swedish MS Registry. The Swedish MS Registry 
is a web-based quality register that includes high quality healthcare data for all MS patients in 
Sweden since 2001152. In addition to demographic data, several parameters of clinical relevance 
are included in the Swedish MS Registry, for example, onset and diagnosis date, fulfillment of 
McDonald’s criteria99, MS clinical course, adverse events, DMT (type, dosage, date of start, 
date and reason of discontinuation), laboratory results, neuroimaging exams, and functional 
and severity scores (Expanded Disability Status Scale, EDSS156, and MS Severity Score, 
MSSS157). Despite participation in the registry being voluntary, both for the patients and their 
attending neurologists, the registry includes about 80% of MS patients in Sweden with 
approximately 18,000 patients in total. The success of the registry is due to its use as clinical 
support tool for the attending neurologists and healthcare personnel. Patients also feel involved 
in their own care by registering patients reported outcome (MS impact scale, MSIS-29158) and 
being able to see a simplified overview of the clinical course of the disease. Data collected in 
this registry appears to be both accurate and complete159.  
5.4  MAIN MEASURES 
5.4.1 Clinical diagnoses 
The Swedish Patient Register146 was the main sources of information to identify patients with 
ALS, other neurodegenerative diseases, psychiatric disorders, and neuromuscular diseases in 
the thesis. We defined individuals as being diagnosed with a certain disease if they had at least 
one recorded discharge diagnosis in the Swedish Patient Register, according to the 
corresponding ICD codes listed in Table 2.  We defined as date of diagnosis the date of the first 
hospital contact regarding that diagnosis. Specialists assign all diagnoses in the Swedish Patient 
Register, which have been shown to have high accuracy146. Additional studies specifically 
validated ALS and MS diagnoses in the Swedish Patient Register and concluded that it is a 
valuable instrument to correctly identify such patients19,160.   
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Table 2. ICD codes used to identify ALS, neurodegenerative diseases, psychiatric disorders, and neuromuscular 
diseases in the Swedish Patient Register. 
  ICD-8  ICD-9 ICD-10 
Amyotrophic lateral sclerosis 
  348.00 335.C G12.2 
Frontotemporal dementia 
  290.11 331.B F02.0, G31.0 
Alzheimer's disease 
  290.10 290.Aa, 290.Ba, 331.A F00, G30 
Other or unspecific dementia 
  290b, 293.0, 293.1 
290.A, 290.B, 290.E, 
290.W, 290.X, 294.B, 
331.C, 331.X 
F01, F02c, F03, F05.1, 
G31.1, G31.8Ad 
Parkinsonian disorders 
  342.00, 342.08, 342.09 332.A, 333.A 
F02.3d, G20, G21.4, 
G21.8, G21.9, G23.1, 
G23.2, G23.9, G25.9, 
G31.8Ad 
Schizophrenia 
  295 295 F20 
Bipolar disorder 
  296.1, 296.3, 296.8 
296.A, 296.C-296.E, 
296.W 
F30, F31 
Depression 
  300.4 300.E, 311 F32e, F33f, F34, F38, F39 
Neurotic disorders 
  300.1-300.3, 300.5-300.9 
300.A-300.D, 300.F-
300.H, 300.W, 300.X 
F40-F42, F44, F45, F48 
Stress-related disorders 
  307 308, 309 F43 
Alcohol abuse/dependence 
  303 303, 305.A F10g 
Drug abuse/dependence 
  304 304, 305.X F11-F19 
Multiple sclerosis 
  n/a 340 G35 
Myasthenia gravis 
  n/a 358.A, 358.B, 358.W G70.0 
Inflammatory polyneuropathies 
  n/a 
357.A, 357.B, 357.W, 
357.X 
G61.0, G61.8, G61.9 
Dermatopolymyositis 
  n/a 710.D, 710.E 
M33.0-M33.2, M33.9, 
G72.4, G73.7 
a If found as primary diagnosis 
b Except 290.10 (Alzheimer’s disease) and 290.11 (Pick’s disease) 
c Except F02.0 (Dementia in Pick’s disease) 
d ICD-10 codes considered both dementia and parkinsonian disorder diagnoses  
e Except F32.2 (depressive psychosis) 
f Except F33.3 (depressive psychosis) 
g Except F10.5 (psychotic state) 
n/a = ICD-8 not applicable during the study period 
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5.4.2 Physical and cognitive fitness 
In Study I, we extracted information on different physical and cognitive fitness variables from 
the Swedish Conscript Register.  
Physical fitness was measured at conscription with a test called “the maximal work test”161. 
During this test, the physical fitness of a person is measured by recording in Watts the 
maximum working capacity (WMAX) that this person can sustain for six minutes on an electric 
bicycle with gradually increasing resistance162,163. As previously suggested52, we analyzed 
WMAX adjusted for weight (WMAX/kg). We defined high levels of weight-adjusted physical 
fitness as above the highest tertile (≥4.25 W/kg). 
We additionally extracted information on body mass index (BMI) and resting heart rate (RHR). 
We derived BMI from weight (kg) and height (m) measured at conscription by dividing weight 
for height in meters squared. We coded individuals as underweight (BMI <18.5 kg/m2), normal 
weight (BMI 18.5-24.99 kg/m2), and overweight or obese (BMI ≥25 kg/m2). RHR was 
measured in beats per minute after 5-10 minutes of rest in the supine position with a cuff 
positioned at the heart level164. 
We included intelligence quotient (IQ) and stress resilience in our definition of cognitive 
fitness. IQ was assessed by several cognitively challenging subtests of progressive difficulty 
measuring general knowledge and verbal, visuospatial, and mechanical ability165. By summing 
the scores of all different tests a general score of IQ was obtained. This score was standardized 
to fit a Gaussian distribution of values ranging from 1 to 9 (so called “stanine scale”) with 
higher values reflecting higher intellectual abilities. We defined high IQ as scores 7-9 on the 
stanine scale.  
Stress resilience was measured during a 20-25 minutes semi-structured interview conducted 
by a trained clinical psychologist166. The aim of this interview was to assess the ability to cope 
with stress during armed combat167 by evaluating different psychological functions domains 
(mental energy, emotional control, social maturity, and active/passive interests). For example, 
psychologists gave a high stress resilience score if during the interview they assessed emotional 
stability, persistence, ability to contribute to group cohesion, or being able to cope with loss of 
personal freedom. Akin to IQ, this score was standardized into a stanine scale with higher 
values reflecting better abilities to cope with stress. We defined high stress resilience as scores 
7-9 on the stanine scale. The Swedish National Defense Research Institute found a high 
interrater-reliability of stress resilience by comparing the scores with army service records at 
the end of military service168.  
5.4.3 Antidepressants prescription 
In Study IV, we identified patients undergoing pharmacological treatment for depression from 
the Swedish Prescribed Register151. Our definition of antidepressants was restricted to SSRIs 
(ATC: N06AB). We restricted our definition to SSRIs because they are first-line treatment for 
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depression in MS169-171, and because other antidepressants such as tricyclic antidepressants 
(TCAs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed 
among MS patients for neuropathic pain. To increase validity, we only coded this variable as 
positive for individuals who had been prescribed SSRIs twice. Identifying patients undergoing 
pharmacological treatment for depression also allowed us to capture patients who might not 
have received a diagnosis from a specialist in the Swedish Patient Register (i.e., depressed 
individuals who only met with the general practitioner). 
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6 METHODS 
6.1 STUDY DESIGNS AND CORRESPONDING STATISTICAL METHODS 
Because the etiology of ALS and MS remains unknown, large-scale population-based 
observational studies are important to help uncover clues to their origins. Population-based 
observational studies include patients of all ages and with all forms of the disease, in contrast 
to clinical studies that are often biased toward including younger ALS patients with slower 
disease progression172 or MS patients with variable disease course173.  
6.1.1 Cohort studies, Cox model, and flexible parametric model 
A population-based prospective cohort design, with complete and long-term follow-up, allows 
to identify potential precursors several years or decades before the disease is diagnosed, and to 
collect information about exposure variables long before the outcomes of interest have 
occurred. Such data might offer important clues, as they are collected independently from the 
later outcome development and are not hampered by recall bias.  
Working with longitudinal data allows us to use time-dependent statistical models such as Cox 
regression, which compares the hazard function of different exposure levels while allowing for 
controlling of multiple potential confounders and the underlying time-scale. The Cox 
regression model, however, assumes that the difference between the hazard rates of different 
exposure groups is proportional over time, which is not always the case. This assumption can 
be circumvented by using flexible parametric models, which involve fitting an interaction 
between the covariates and time. Other advantages of flexible parametric models over Cox 
models include the possibility to observe how the hazard functions might change over time174. 
This is of great medical interest, as the association of certain risk factors with a specific disease 
might be directly related to the time-course of a specific disease. 
6.1.2 Nested case-control studies and logistic regression 
Although the aforementioned prospective cohort design has many advantages, when presented 
with a large cohort and a rare outcome such as ALS, the nested case-control design is a 
computationally efficient alternative. The nested case-control design includes all cases and a 
pre-defined number of randomly selected outcome free-controls, sampled from a parent cohort. 
In this study design, logistic regression is suitable to compare the risk of ALS in individuals 
exposed to certain factor, compared to individuals who are unexposed to the factor. In our case, 
it is possible to use logistic regression because the outcome investigated can be classified as a 
binary variable, having or not having a diagnosis of ALS175.   
6.1.3 Medical records review and descriptive statistics 
Large-scale Swedish register-based studies rarely collect detailed phenotypic, clinical, or 
biological information, given the (usually) nationwide and administrative nature of data 
collection. However, it is possible to retrospectively collect detailed information among a 
smaller set of individuals included in the register-based studies, through medical records 
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review. One can compare frequency differences between groups of individuals using the Chi-
square test and estimate mean differences using Student’s t-test. This kind of analysis can 
provide detailed information on specific subset of patients, which is relevant for diseases of 
uncertain etiology such as ALS. 
6.2 METHODS STUDY I  
We identified all males aged 17-20 who attended conscription examination from 1968 to 2010, 
during which time military conscription was mandatory for all Swedish males. This ALS-free 
cohort consisted of 1,901,807 males. We excluded conscripts who died (N=6,531) or emigrated 
(N=10,634) before the beginning of follow-up. We also excluded conscripts without 
information on physical fitness, i.e. WMAX/kg, BMI, RHR, IQ, and stress resilience (N= 
46,266), leading to a final sample of 1,838,376 conscripts (97.5% of the initial cohort). 
We set the beginning of follow-up to January 1st 1987. If the conscripts attended conscription 
examination after January 1st 1987, we followed them from the date of conscription 
examination. We set the end of follow-up at December 31st 2013. If the conscripts were 
diagnosed with ALS, died, or emigrated out of Sweden before the end of follow-up, we stopped 
following them on the first date of ALS diagnosis, death, or emigration (whichever came first).  
 
 
Figure 2. Flow-chart of identification of the study participants of Study I.  
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Statistical analysis 
We computed the correlation among the exposure variables (WMAX/kg, BMI, IQ and stress 
resilience) using Spearman correlation coefficient (ρ). We used Spearman correlation 
coefficient because it does not require continuous-level assumptions.  
We conducted two separate flexible parametric models to examine if high levels of physical 
(WMAX/kg and BMI) and cognitive fitness (IQ and stress resilience) would affect the age-
specific risk of ALS, compared to lower levels of fitness. The full model for physical fitness 
included as covariates calendar period of conscription examination, parental socioeconomic 
status (SES), RHR, and was mutually adjusted for WMAX/kg and BMI. The full model for 
cognitive fitness included calendar period of conscription examination, parental SES, and was 
mutually adjusted for IQ and stress resilience. We used attained age as the time scale in all 
models and derived hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). We 
picked five degrees of freedom for the baseline hazard and three degree of freedom for the 
time-dependent effect174. 
The adjustment for calendar period of examination (1968-1980, 1981-1993, and 1994-2010) 
was necessary because the procedures of assessment of the different parameters in the 
Conscript Register varied during the years, for example tests to assess IQ changed in 1994176. 
We added RHR into the physical fitness model because of its suggested association with 
ALS177 and correlation with physical fitness178. Because all conscripts were aged 17-20, we 
adjusted for their parental SES instead of their own SES, after identifying mothers and fathers 
of the conscripts from the Swedish Multi-Generation Register and identifying the parents’ SES 
information through the Swedish Population and Housing Censuses.  
We considered statistically significant associations with two-sided P-values <0.05. 
6.3 METHODS STUDY II 
In Study II, we followed all individuals identified from the Swedish Multi-Generation Register, 
who were born in Sweden during 1932-2013 (N=8,575,515), from January 1st 1990 until 
December 31st 2013. If an individual was born after January 1st 1990, we followed him/her 
from date of birth. Individuals who were diagnosed with ALS (N=662), died (N=120,612), or 
emigrated out of Sweden (N=186,670) before the beginning of follow-up were not included in 
the study base (N=8,269,319). If an individual was diagnosed with ALS, died, or emigrated out 
of Sweden before end of follow-up, we stopped following him/her on date of first ALS 
diagnosis, death, or migration (whichever came first). 
Within the study base, we conducted a nested case-control study and defined as cases all the 
patients diagnosed with ALS during follow-up (N=3,648). By incidence density sampling, ten 
controls were randomly selected and individually matched to each case by sex, year and month 
of birth, and county of birth (N=36,480). To serve as an eligible control, an individual had to 
be without ALS, alive, and living in Sweden on the date of ALS diagnosis of the corresponding 
ALS case. For cases and controls, we defined as index date the date of ALS diagnosis of the 
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cases. In this nested case-control study, we assessed the association between neurodegenerative 
and psychiatric diseases and the future risk of ALS.  
We also assessed the association between neurodegenerative and psychiatric diseases and being 
a relative of an ALS patient. Hence, we conducted a nested case-control study of the relatives 
of the cases (N=19,760) and controls (N=198,794) of the above nested case-control study. We 
identified the parents, siblings, half-siblings, and children of the cases and controls through the 
Swedish Multi-Generation Register.  
We also examined the association between being exposed to an ALS diagnosis and the risk of 
subsequently being diagnosed with neurodegenerative and psychiatric diseases. After 
excluding all individuals from the above nested case-control studies who were diagnosed with 
any neurodegenerative or psychiatric diseases before ALS diagnosis, we conducted a follow-
up study of the ALS patients (N=3,169) and ALS-free individuals (N=33,110), and a follow-
up study of the relatives of the ALS patients (N=13,313) and the relatives of the ALS-free 
individuals (N=130,321). In both follow-up studies, the participants were followed from index 
date to date of diagnosis of neurodegenerative or psychiatric diseases, emigration, death, or end 
of follow-up on December 31st, 2013 (whichever came first).  
Statistical analysis 
In the nested case-controls studies, to measure the association between neurodegenerative and 
psychiatric diseases with future risk of ALS, we fitted conditional logistic regression models 
to estimate odds ratios (ORs), and corresponding 95% CIs of ALS and of becoming a relative 
of an ALS patient. In the nested case-control study, the models were automatically adjusted for 
sex, year and month of birth, and county of birth, as these were the variables the controls were 
matched to the cases on. In the nested case-control study of the relatives, we adjusted for both 
sex, year and month of birth, and county of birth of the index person, as well as for sex, year 
and month of birth, and county of birth of the relatives.  
In the follow-up studies, to measure the risk of being diagnosed with neurodegenerative or 
psychiatric diseases after being exposed to ALS, we fitted Cox proportional hazard regression 
models to derive HRs and corresponding 95% CIs by comparing ALS patients to ALS-free 
individuals, and relatives of ALS patients to relatives of ALS-free individuals. We set attained 
age as the underlying time scale in all models. In the follow-up study, the models were further 
adjusted for sex and county of birth, and in the follow-up study of the relatives the models were 
further adjusted for sex and county of birth of the index person, as well as for sex, year and 
month of birth, and county of birth of the relatives. 
We tested the assumption of proportional hazards using Schoenfeld residuals and considered 
statistically significant associations with two-sided P-values ≤0.05. 
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Figure 3. Flow-chart of identification of the study participants of the nested case-control studies and follow-up 
studies of Study II. 
 
6.4 METHODS STUDY III 
We requested from the Swedish National Board of Health and Welfare a list of personal identity 
numbers of all the patients in the Swedish Patient Register who had recorded diagnoses of both 
ALS and either MS/MG/IP/DMPM during 1991-2014 (N=263). From the Swedish National 
Board of Health and Welfare, we also received a list of all the hospitals and departments that 
these patients were visited at. We then mailed the chiefs of departments of all the hospitals and 
requested the medical records of these patients, identified by their personal identity numbers. 
We sent reminders to the chiefs of departments who did not get back to us within three months. 
Once we received all the medical records available for each patient (N=245), three experienced 
neurologists, specialized in ALS and neuroinflammatory diseases, independently reviewed the 
medical records. Decisions of diagnostic accuracy were made by consensus. Because PLS is 
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gaining recognition as a sub-phenotype of ALS, the neurologists validated a patient meeting 
criteria of PLS as an ALS patient179.  
 
Figure 4. Flow-chart of data collection and diagnostic accuracy decisions of the study participants of Study III. 
 
Statistical analysis 
We extracted detailed clinical data from the medical records of patients with validated 
concurrent ALS and MS/MG/IP/DMPM. We summarized their clinical ALS characteristics, 
the order in which the concurrent diseases occurred (i.e., which diagnosis was given first), and 
how much time passed in between diagnoses.  
Additionally, we examined if patients with a concurrent diagnosis of ALS and 
MS/MG/IP/DMPM represented a special group of patients that differed in terms of clinical 
characteristics of ALS. To assess this, we compared patients with concurrent ALS and 
MS/MG/IP/DMPM against an independent sample of patients who were diagnosed with only 
ALS. This group consisted of 271 ALS patients visited in Stockholm during 2013-2014. Our 
group previously performed a validation study of ALS diagnosis of these patients based on a 
detailed extraction of data from medical records19. For the categorical variables, we used Chi-
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square test or Fisher’s exact test (if the expected frequencies were less than or equal to five) to 
test the differences between two groups, and for non-normally distributed continuous variables 
we used the Wilcoxon test. We considered statistically significant associations with two-sided 
P-values <0.05. 
6.5 METHODS STUDY IV 
In Study IV, our study population consisted of all patients diagnosed with RRMS in the 
Swedish MS Registry, who were born in Sweden and living in Sweden during January 2005-
September 2018 (N=6,000). We followed this cohort from start of their first DMT until end of 
follow-up on December 31st 2018. We did not include in the study participants individuals with 
either a depression diagnosis in the Swedish Patient Register or an antidepressants prescription 
in the Prescribed Drug Register before start of their first DMT (N=789). We also excluded 
individuals who withdrew from the MS Registry before start of their first DMT (N=2), or the 
ones that did not have any recorded DMT (N=342), leaving 4,867 RRMS patients in the final 
analyses.  
 
 
Figure 5. Flow-chart of identification of the study participants of Study IV. 
 
Statistical analysis 
Our main aim was to assess if the risk of depression or prescription of antidepressants varied 
according to different DMTs. Hence, we fitted Cox proportional hazard regression models and 
calculated HRs of depression or antidepressant prescription and corresponding 95% CIs in 
relation to DMTs. We considered DMTs as time-varying exposure because RRMS patients 
frequently switch DMTs during the course of the disease for various lengths of time. A patient 
was considered exposed to a certain DMT from the date of DMT start to the date of DMT 
discontinuation. We compared all the different time periods when patients were on dimethyl 
fumarate, fingolimod, natalizumab, rituximab, or other DMTs, against the time periods when 
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patients were on interferons, which were our reference DMT. Other DMTs analyzed as a group 
were alemtuzumab, daclizumab, glatiramer acetate, hematopoietic stem cell transplantation, 
novantrone, and teriflunomide. In this analysis, patients re-entered the study on the start date 
of each DMT. Each patient was followed until date of depression diagnosis or antidepressants 
prescription, DMT discontinuation, loss to follow-up (withdrawal from the Swedish MS 
registry, death, or migration out of Sweden), or end of follow-up.  
We also examined if being exposed to depression or antidepressant prescription had an effect 
on DMT discontinuation or MS relapse after DMT initiation. Again, we fitted Cox proportional 
hazard regression models and separately calculated HRs of DMT discontinuation or MS relapse 
and corresponding 95% CIs. We considered depression or prescription of antidepressants as 
time-varying exposures. A patient was considered exposed from date of depression diagnosis 
or from date of first prescription of antidepressants. Similar to the above analysis, each patient 
re-entered the study on the start date of each DMT. Each patient was followed until date of 
DMT discontinuation, date of MS relapse, loss to follow-up (withdrawal from the Swedish MS 
registry, death, or migration out of Sweden), or end of follow-up. Because we aimed to examine 
if exposure to depression or antidepressants prescription had an effect on DMT adherence, we 
censored follow-up for observations where the reason of DMT discontinuation included stable 
condition, pregnancy, or planned pregnancy, instead of using these as discontinuation 
outcomes. Two patients were excluded from the models where the outcome of interest was MS 
relapse (N=4,865) because they experienced an MS relapse on the day of DMT start.  
We set time since start of DMT as the underlying time scale in all analyses so that all models 
would be automatically adjusted for it. Additionally, we progressively built multivariable Cox 
models including other potential confounders: sex, age at start of DMT, geographic region of 
treatment (as an indicator of SES), bipolar disorder diagnosis (given its association with 
depression180 and potential association with MS122), MS severity (assessed via the scales EDSS, 
MSIS-29, and MSSS), MS relapse at symptoms onset, and line of DMT. Given that EDSS, 
MSIS-29, and MSSS are repeatedly recorded in the Swedish MS Registry, we selected in all 
analyses the closest scores that were assessed prior to DMT start of each observation. In the 
models where we assessed the risk of DMT discontinuation or MS relapse, if a patient was 
exposed to depression or prescription of antidepressants, we selected the closest EDSS, MSIS-
29, and MSSS scores recorded both prior to DMT start and date of depression diagnosis or date 
of prescription of antidepressants.  
In all analyses, given that each patient contributed to multiple time periods of observation every 
time a patient started a new DMT, we used a sandwich estimator to estimate unbiased standard 
errors.  
We considered statistically significant associations with two-sided P-values ≤0.05. 
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7 ETHICAL CONSIDERATIONS 
In Studies I and II we used linkage of different existing population-based Swedish registers 
that contain data on intelligence, neurodegenerative and psychiatric diagnoses, familial links, 
as well as a large amount of other sensitive information. The Swedish national registers have 
been established without individual informed consent with the aim of benefiting the society. In 
the Nordic countries, large-scale epidemiological studies have been conducted since the 
establishment of national registers with the general approval from the population, mainly due 
to a high degree of public trust in research154. A Swedish qualitative study, investigating 
consent issues in register-based data linkage, reported that study participants wished to be 
contacted prior to the beginning of the study181. However, the participants themselves did not 
see active consent as of primary importance and expressed concern over the possibility of 
missing data due to withdrawal181.  
In Study IV we also used a data linkage of population-based Swedish registers, but clinical and 
treatment data on the study population was extracted from the Swedish MS Registry. Unlike 
the Swedish national registers, participation in the Swedish MS Registry is voluntary, both for 
the patients and their attending neurologists. Specifically, the clinical documentation is 
collected locally and merged into a compiled data set that constitutes the Swedish MS Registry. 
Patients are informed about this procedure and have the possibility to withdraw from the 
registry at any time, if desired.  
The record linkages used for Studies I, II, and IV, have obtained approval by the Regional 
Ethical Review Board in Stockholm, which recognized that although active consent fulfills the 
moral and legal premises of study participants’ autonomy, technical and economical limitations 
arise from having to inform millions of individuals. Overall, the decision to not seek informed 
consent for the record linkages has been approved after taking into account the balance between 
gain of knowledge, positive long-term effects on the community, and violation of integrity of 
the participants. 
In Study III, we used sensitive data from a medical records review containing detailed medical 
information. Although by accessing medical records we were subjected to the Secrecy Act, the 
project was granted ethical permit by the Regional Ethical Review Board in Stockholm, which 
waived us from seeking informed consent. This exemption, regulated in the Personal Data Act 
(in place at the time of ethical application for this project) states that data is personal when it is 
possible to connect it to a person who is alive. Because ALS is a disease with fast and fatal 
progression, with patients dying on average within three years after diagnosis, we expected the 
majority of our study participants to no longer be alive at the time of the study.  
When working with register-based data the risk of violation of integrity is reduced since data 
are de-identified with an internally created identifier. In Study III, we did receive the actual 
personal identity numbers of all the study participants, in order to access their medical records. 
However, once we obtained the medical records, we de-identified the patients and assigned 
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them an internally created identifier to secure the privacy of the participants during data 
analysis.  
Further security measures are in place in order to ensure a correct processing of personal data 
in according to the European General Data Protection Regulation. Anyone who handles 
personal data is subject to confidentiality, and only the assigned database administrator has the 
access to all data, whereas researchers only have limited access to the information strictly 
necessary for the project. We implemented additional appropriate technical and organizational 
actions, such as IT protection and good data management by keeping data stored on secure 
servers and following good data management guidelines in place at the department.  
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8 MAIN RESULTS 
8.1 STUDY I – PHYSICAL AND COGNITIVE FITNESS ARE ASSOCIATED WITH 
ALS 
At conscription examination, 65.40% of the 1,838,376 conscripts included in the study were 
aged 18, 37.32% went through conscription examination during 1981-1993, 33.27% had a 
WMAX/kg between 3.63 and 4.24 W/kg, 74.26% had a normal BMI, 54.20% had a medium 
level IQ, and 57.77% had a medium level stress resilience.  
At conscription examination, the correlation between WMAX/kg and BMI was negative (ρ=-
0.23; p<0.001), whereas the correlation between IQ and stress resilience was positive (ρ=0.37; 
p<0.001). Correlation coefficients among all physical and cognitive fitness variables used in 
the analyses are reported in Table 3, all of which are statistically significant (p<0.001). 
 
Table 3. Spearman correlation coefficients between physical and cognitive fitness variables. 
 WMAX/kg BMI IQ Stress resilience 
WMAX/kg n/a -0.23 0.15 0.30 
BMI -0.23 n/a -0.05 0.11 
IQ 0.15 -0.05 n/a 0.37 
Stress resilience 0.30 0.11 0.37 n/a 
 
We identified 439 newly diagnosed ALS patients during follow-up. On average the age at ALS 
diagnosis was 48 years (range 21-62 years, standard deviation=8.74, SD).  
Conscripts with high WMAX/kg (≥4.25 W/kg) had a 66-75% increased risk of being diagnosed 
with ALS before age 44 (range of HRs= 1.66, 95% CI 1.01-2.82 and 1.75, 95% CI 1.01-3.05), 
compared to conscripts with lower WMAX/kg, after adjusting for BMI and RHR (Figure 6). 
Overweight or obese conscripts had a 50-58% reduced risk of being diagnosed with ALS after 
age 41 (range of HRs= 0.42, 95% CI 0.19-0.96 and 0.50, 95% CI 0.26-0.94), as compared to 
normal weight and underweight conscripts, after adjusting for WMAX/kg (Figure 6). The 
association between WMAX/kg and ALS was statistically significant at age 41-43 years, 
whereas the association with BMI was statistically significant at age 42-48 years. 
Conscripts with high IQ (i.e., those scoring above the highest tertile) had a 33-81% increased 
risk of being diagnosed with ALS after age 55 (range of HRs= 1.33, 95% CI 1.00-1.78 and 
1.81, 95% CI 1.01-3.30), compared to conscripts with lower IQ, holding stress resilience 
constant (Figure 7). Conscripts with high stress resilience (above the highest tertile) had a 29-
53% reduced risk of being diagnosed with ALS before age 56 (range of HRs= 0.47, 95% CI 
0.28-0.79 and 0.71, 95% CI 0.53-0.97), as compared to conscripts with lower stress resilience, 
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holding IQ constant (Figure 7). Specifically, the association for IQ was statistically significant 
at age 56-61 years, whereas the association for stress resilience was statistically significant at 
age 46-55 years. 
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WMAX/Kg 
 
BMI 
 
Figure 6. HRs and corresponding 95% CIs of ALS, for WMAX/kg (≥4.25 W/kg versus <4.25 W/kg; model 
adjusted for calendar period of conscription examination, parental SES, BMI, and RHR), and for BMI (overweight 
or obese vs. lower BMI; model adjusted for calendar period of conscription examination, parental SES, and 
WMAX/kg).  
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IQ 
 
Stress resilience 
 
Figure 7. HRs and corresponding 95% CIs of ALS, for IQ and stress resilience above the highest tertile versus 
lower IQ and stress resilience (model adjusted for calendar period of conscription examination, parental SES, and 
mutually adjusted for IQ and stress resilience).  
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8.2 STUDY II – OVERLAP OF NEURODEGENERATIVE AND PSYCHIATRIC 
DISEASES AMONG ALS PATIENTS AND THEIR FAMILIES 
We identified 3,648 ALS patients during the study period, who on average were diagnosed 
with ALS at age 60 years (SD=11.30). The majority of the patients were males (59.90%). 
Because the 36,480 controls were matched to the cases on sex, year and month of birth, and 
county of birth, they had the same sex, age at index date, and county of birth distribution. The 
age at index date and sex of parents, siblings, half-siblings, and children of ALS patients were 
comparable to the ones of parents, siblings, half-siblings, and children of ALS-free controls. 
On average, we identified 1.8 parents, 1.5 siblings, 0.2 half-siblings, and 1.9 children for each 
ALS patient and for each ALS-free control. 
ALS patients, compared to ALS-free controls, had increased risk of all neurodegenerative 
diseases investigated (OR=3.58, 95% CI=2.89-4.44 before index date; HR=3.95, 95% 
CI=2.92-5.34 after index date), as well as depression (OR=1.51, 95% CI=1.28-1.77 before 
index date; HR=2.78, 95% CI=2.05-3.79 after index date), neurotic disorders (OR=1.53, 95% 
CI=1.27-1.84 before index date; HR=3.07, 95% CI=2.23-4.24 after index date), and drug/abuse 
dependence (OR=1.80, 95% CI=1.36-2.38 before index date; HR=2.0, 95% CI=1.2-3.4 after 
index date; Figure 8 and Figure 9). The diseases with the strongest associations with ALS in 
descending order of magnitude were FTD, PD, other or unspecific dementia, and AD. 
The year before ALS diagnosis was the time window with the strongest associations of FTD 
(OR=40.0, 95% CI=11.3-141.8), PD (OR=9.5, 95% CI=5.2-17.2), other or unspecific dementia 
(OR=12.1, 95% CI=7.0-20.7), AD (OR=4.7, 95% CI=2.5-9.0), depression (OR=4.8, 95% 
CI=3.3-7.0), neurotic disorders (OR=4.8, 95% CI=3.0-7.5), drug abuse/dependence (OR=2.8, 
95% CI=1.5-5.4) with ALS risk. These associations were also statistically significant up to five 
years before ALS diagnosis, although of lower magnitude. Similarly, the year after ALS 
diagnosis was the time window with the strongest associations between ALS and any 
neurodegenerative or psychiatric diseases (HR=5.02, 95% CI=3.91-6.45), extending up to five 
years after ALS diagnosis (HR=2.31, 95% CI=1.75-3.06). During the year before ALS 
diagnosis we also found a positive association of schizophrenia (OR=5.0, 95% CI=1.2-20.1) 
and stress-related disorders (OR=2.6, 95% CI=1.3-5.5) with ALS risk. The association between 
ALS diagnosis and stress-related disorders was statistically significant up to five years after 
ALS diagnosis (HR=2.9, 95% CI=1.2-6.9), with again the strongest association observed 
during the year following ALS diagnosis (HR=5.5, 95% CI=2.3-13.4).  
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ALS patients vs. ALS-free controls - Before index date 
 
Figure 8. ORs and corresponding 95% CIs of neurodegenerative and psychiatric diseases among ALS patients 
and matched controls before index date (model adjusted for age, sex, and county of birth).  
 
ALS patients vs. ALS-free controls - After index date 
 
Figure 9. HRs and corresponding 95% CIs of neurodegenerative and psychiatric diseases comparing ALS patients 
against ALS-free individuals after index date (model adjusted for age, sex, and county of birth).  
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Relatives of ALS patients, compared to relative of ALS-free individuals, had a higher risk of 
neurodegenerative diseases before (Figure 10) and after (Figure 11) the index date. However, 
this association was only statistically significant for siblings (OR=1.41, 95% CI=1.02-1.96 
before index date; HR=1.76, 95% CI=1.31-2.36 after index date), but not for parents and 
children. In contrast, children of ALS patients, compared to children of ALS-free individuals, 
had a higher risk of psychiatric diseases before (OR=1.11, 95% CI=1.01-1.23; Figure 10) and 
after (HR=1.11, 95% CI=1.00-1.25; Figure 11) the index date. Half-siblings of ALS patients 
did not differ in terms of risks of any neurodegenerative or psychiatric diseases, compared to 
half-siblings of ALS-free individuals, neither before (OR=0.66, 95% CI=0.42-1.07) nor after 
(HR=1.2, 95% CI=0.6-2.5) the index date. 
 
Relatives of ALS patients vs. relatives of ALS-free controls - Before index date 
 
Figure 10. ORs and corresponding 95% CIs of neurodegenerative and psychiatric diseases among relatives of 
ALS patients and relatives of matched controls before index date (model adjusted for age, sex, and county of birth). 
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Relatives of ALS patients vs. relatives of ALS-free controls - After index date 
 
Figure 11. HRs and corresponding 95% CIs of neurodegenerative and psychiatric diseases comparing relatives of 
ALS patients against relatives of ALS-free individuals after index date (model adjusted for age, sex, and county 
of birth of the relatives, as well as age, sex, and county of birth of the proband individuals).  
 
8.3 STUDY III – OVERLAP OF NEUROMUSCULAR DISEASES AND ALS 
After receiving medical records from 245 out of the 263 patients who were recorded in the 
Swedish Patient Register as having a diagnosis of both ALS and MS/MG/IP/DMPM, we had 
enough medical information to validate the diagnoses for 242 of them. We first validated the 
ALS diagnoses of these patients. Among the 151 patients who were confirmed as having an 
ALS diagnosis (62.4%), we validated the concurrent diagnoses of MS/MG/IP/DMPM. We 
found that 26 patients were misdiagnosed with MS, 26 patients were misdiagnosed with MG, 
54 patients were misdiagnosed with IP, and 18 patients were misdiagnosed with DMPM. The 
diagnoses of concurrent ALS and MS/ MG/IP/DMPM were confirmed for 12 patients with 
ALS/MS, nine patients with ALS/MG, four patients with ALS/IP, and three patients with 
ALS/DMPM. 
Of the 28 patients with a confirmed concurrent diagnosis of ALS and MS/MG/IP/DMPM, 17 
were women. The majority of patients (79%) were first diagnosed with MS/MG/IP/DMPM, 
and then, after a median of 6 years (range 0-53), with ALS. Among the minority of patients 
diagnosed with ALS first (21%), the median time interval to MS (N=2) or MG (N=4) diagnosis 
was shorter than one year (range 0-8).  
Five ALS patients had the sub-phenotype “PLS”, three had concurrent PLS/MS, and two had 
concurrent PLS/MG. Among the 12 patients with concurrent ALS/MS, there was enough 
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information to assess MS subtypes for nine of them, divided among PPMS (N=3, 33.3%), 
SPMS (N=3, 33.3%), and RRMS (N=3, 33.3%). Seven of the nine patients with concurrent 
ALS/MG had generalized MG (77.8%), whereas two presented with bulbar MG (22.2%). 
Among the four patients with concurrent ALS/IP there was enough information to assess IP 
subtypes for three of them: two presented with Acute Motor Axonal Neuropathy (66.7%), a 
variant of GBS, whereas one had Chronic Inflammatory Demyelinating Polyneuropathy 
(CIDP, 33.3%). Polymyositis accounted for two of the three ALS/DMPM patients (66.7%), 
whereas unspecified myositis for one of them (33.3%). 
The patients with confirmed concurrent ALS and MS/MG/IP/DMPM differed in terms of 
clinical characteristics of ALS from patients diagnosed with only ALS. They were 8.5 years 
older at ALS onset (median age 70.5 years; P=0.014), presented with a 17.6% higher 
prevalence of bulbar ALS onset (46.4%; P=0.037), and had a 23.5% lower prevalence of 
riluzole treatment (64.3%; P=0.001). When treated with riluzole, they had an 18 months shorter 
median time between ALS diagnosis and first riluzole prescription (1 month; P<0.0001), 
compared to patients with only ALS. They had also a 30.1% lower prevalence of treatment 
with non-invasive ventilation (17.9%; P=0.002), compared to patients with only ALS. 
However, sex (P=0.174), time between ALS onset and diagnosis (P=0.571), cognitive 
impairment symptoms before ALS diagnosis (P=0.450), use of invasive ventilation (P=1.000), 
and survival (P=0.579) did not differ between patients with concurrent ALS and 
MS/MG/IP/DMPM and patients with only ALS.   
8.4 STUDY IV – DEPRESSION IN RRMS 
Of the 4,867 RRMS patients included in Study IV, there were more women (69.24%) than men 
(30.76%). On average, the age at RRMS diagnosis was 35.98 years (SD=10.89), and the age at 
start of first DMT was 36.30 years (SD=10.84). More than half of the patients (55.62%) had 
interferons as their first DMT, followed by rituximab (12.68%), dimethyl fumarate (10.19%), 
natalizumab (9.97%), other DMTs (9.08%), and fingolimod (2.47%).  
When treated with rituximab, patients had a 47% lower risk of being diagnosed with depression 
or receiving a prescription of antidepressants, as compared to treatment periods with interferons 
(HR=0.53, 95% CI 0.36-0.78; Figure 12), holding constant sex, age at start of DMT, geographic 
region of treatment, bipolar disorder diagnosis, MS severity, relapse at MS debut, and line of 
DMT. When treated with “other DMTs”, these patients also had a reduced risk of depression 
and antidepressants prescription (HR=0.63, 95% CI 0.41-0.97; Figure 12).  
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DMTs and risk of depression or antidepressants prescription among RRMS patients 
 
Figure 12. HRs and corresponding 95% CIs of depression or antidepressants prescription during treatment periods 
with dimethyl fumarate, fingolimod, natalizumab, rituximab, or other DMTs, compared to treatment periods with 
interferons (model adjusted for time since DMT start, sex, age at start of DMT, geographic region of treatment, 
bipolar disorder, MS severity, relapse at MS debut, and line of DMT). 
 
In the full model adjusted for sex, age at start of DMT, geographic region of treatment, bipolar 
disorder diagnosis, MS severity, MS relapse, and line of DMT, we did not find a risk alteration 
of DMT discontinuation or MS relapse after DMT initiation when comparing patients with a 
diagnosis of depression or a prescription of antidepressants to patients without a diagnosis of 
depression or a prescription of antidepressants (Table 4).  
 
Table 4. Associations of depression or antidepressants prescription with the risk of DMT 
discontinuation and MS relapse among RRMS patients. 
 DMT discontinuation MS relapse 
 HR (95% CI)a HR (95% CI)a 
No depression diagnosis Ref. Ref. 
Depression diagnosis 1.12 (0.86-1.44) 0.82 (0.40-1.66) 
No antidepressants prescription Ref. Ref. 
Antidepressants prescription 1.05 (0.88-1.26) 0.72 (0.44-1.18) 
a Model adjusted for time since DMT start, sex, age at start of DMT, geographic region of 
treatment, bipolar disorder, MS severity, relapse at MS debut, and line of DMT. 
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9 DISCUSSION 
9.1  PHYSICAL AND COGNITIVE FITNESS PREDICT EARLY ONSET ALS 
Using a nationwide representative cohort of Swedish male conscripts, we found that a specific 
profile of physical and cognitive fitness already in young adulthood is associated with 
subsequent diagnosis of ALS.  
Specifically, we found that high levels of physical fitness and IQ, but lower BMI and stress 
resilience, were associated with early onset ALS. We concluded that these associations were 
significant for early onset ALS because in our cohort we identified a group of ALS patients 
who were on average 48 years old at ALS diagnosis, whereas the mean age at diagnosis of ALS 
reported in European population-based studies is about 65 years182. Patients with early-onset 
ALS differ from other ALS patients in terms of pathological features and survival183.  
Our findings confirm the results of Mattsson et al.52, who found an association between 
physical fitness and ALS. We further show that the association of exposure to greater physical 
fitness in early life might be a specific risk factor for ALS diagnosis before age 45 years, but 
not thereafter. This finding dovetails with the observation that soccer players are at an increased 
risk of early onset ALS47-51. Intensive exposure to non-genetic risk factors in early life, such as 
physical activity, might be one of the underlying reasons for early onset ALS, in addition to a 
genetic predisposition183.  
We also confirmed that BMI is inversely associated with ALS risk184 and showed that 
metabolic changes among ALS patients might occur as early as at age 18. 
We are the first to empirically confirm the clinical impression that ALS patients have a specific 
cognitive profile by showing that high levels of IQ, before secondary education is obtained, are 
associated with an increased risk of ALS. IQ is therefore possibly one of the reasons leading to 
high educational attainment among some ALS patients185. We are also the first to show that a 
lower level of stress resilience at young age is associated with increased risk of later ALS. This 
provides further support to the hypothesis that psychological stress might contribute to the 
initiation of motor neuron degeneration186.  
It is interesting to note that our findings of a specific physical and cognitive fitness profile in 
early life might be specific to ALS but not to other neurodegenerative diseases. For example, 
similar studies conducted in the Swedish Conscript Register found that high levels of physical 
fitness in early life was associated with a lower risk of MS, and that there was no association 
of BMI, IQ, or stress resilience with the risk of MS187.  
9.2 SHARED ETIOLOGY OF NEURODEGENERATIVE DISEASES AND 
STRESS REACTION OF ALS DIAGNOSIS  
Using two nested case-control and follow-up studies from a population-based study sample, 
we showed that ALS patients suffered from an increased risk of neurodegenerative and 
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psychiatric diseases both before and after ALS diagnosis. The increased risk of 
neurodegenerative diseases was also found among first-degree relatives of ALS patients, 
whereas the increased risk of psychiatric disorders was observed only among children of ALS 
patients.  
We confirmed previous research showing an association between some neurodegenerative 
diseases after ALS diagnosis77,78 and further extended these findings by highlighting that the 
increased risk of several neurodegenerative diseases is present years before until years after 
ALS diagnosis. We found that this association was not limited to ALS patients but also, as 
shown previously79, to their first-degree relatives. Because first-degree relatives share about 
50% of the segregating genes, these results provide evidence for a shared genetic etiology 
between different neurodegenerative diseases79-81. The accumulation of protein aggregates 
commonly found in the brain of patients with neurodegenerative diseases could lead to 
neuroinflammation188 and might therefore be one of the possible underling mechanisms. The 
observation that the association between neurodegenerative diseases and ALS was present even 
five years before ALS diagnosis is a unique finding, which argues against misdiagnosis of 
neurodegenerative diseases and surveillance bias as the pure explanations for these findings.  
We also confirmed the results of previous studies regarding an association between psychiatric 
disorders and ALS88,89. Our unique contribution includes showing that this association was 
present already five years before diagnosis and peaked during the year before and the year after 
ALS diagnosis. This might imply that in addition to non-motor symptoms of ALS mimicking 
psychiatric disorders83, a stress reaction might occur along with the onset of ALS symptoms 
and in relation to receiving a fatal diagnosis. The significantly increased risk of schizophrenia 
during the year preceding ALS diagnosis might be explained by shared genetics, as suggested 
by a GWAS study189.  
We did not confirm the previously reported inverse association between alcohol abuse and ALS 
risk92,190-192. Our results might have suffered from lack of adjustment for smoking and diet. 
However, we did confirm the previously suggested association between use of opioids and 
ALS93, and further extended it to drug abuse/dependence including medicines, cocaine, 
caffeine, opioids, and cannabis. Although depression and stress-related disorders might 
increase the risk of drug abuse/dependence193-195, the association remained after excluding 
individuals with concurrent diagnoses of stress-related disorders and drug abuse/dependence. 
We also found an increased risk of psychiatric disorders among children of ALS patients, but 
not among the other first-degree relatives. This implies that the association might not be driven 
by shared genetics. Instead, the association might be attributable to the psychological distress 
due to high involvement of children of ALS patients in the care of their parents196.  
9.3 NEUROINFLAMMATION AROUND THE MOTOR UNIT MIGHT TRIGGER 
ALS 
By following the entire Swedish population for 23 years, we were able to confirm a concurrent 
diagnosis of ALS and MS/MG/IP/DMPM in 28 patients. Because we showed that the majority 
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of these patients were diagnosed with neuroinflammatory disorders years before ALS 
diagnosis, this provides evidence for the role of neuroinflammation around the motor unit in 
triggering the onset of ALS. We further showed that these patients had different clinical 
characteristics of ALS compared to patients with ALS alone, and they might hence represent a 
specific albeit very small subgroup of ALS.   
Our study, which is the largest to date, replicates past case-reports and epidemiological studies 
showing an overlap between ALS and MS, ALS and MG, and ALS and DMPM57-63,67-70,197-201. 
We are the first to report on the overlap between ALS and GBS as well as ALS and CIDP, 
suggesting that both chronic and acute neuroinflammation around the motor unit might play a 
role in ALS onset. 
Because we were able to describe onset and date of diagnosis of the concurrent 
neuroinflammatory diseases with respect to ALS, this implies that neuroinflammation appears 
to precede rather than follow ALS onset. Furthermore, in a minority of patients where ALS 
was diagnosed before MS and MG, the median time interval between diagnoses was less than 
one year. This might suggest that MS and MG in such patients were formally diagnosed after 
ALS, but were in fact already present before ALS onset.  
When we compared patients with concurrent ALS and MS/MG/IP/DMPM to patients with 
only ALS, we found that concurrent patients were more likely to have bulbar ALS onset, they 
were older at ALS onset, and they were treated less frequently with riluzole and non-invasive 
ventilation. Patients with bulbar onset of ALS present with neurofibrillary tangles, basophilic 
inclusions, and unusual pathology of the extra motor cortical regions202. The higher prevalence 
of bulbar onset patients in the concurrent ALS and MS/MG/IP/DMPM group might explain 
why we found that concurrent patients were less frequently treated with non-invasive 
ventilation, given that they are less likely to tolerate non-invasive ventilation than patients with 
limb onset203. However, it is also possible that this difference might be due to fewer respiratory 
symptoms or a slower disease progression. The hypothesis of neuroinflammation around the 
motor unit playing a role in triggering ALS onset is further supported by the older age at ALS 
onset as a possible consequence of longer induction time in this subgroup of patients.  
By validating the medical records of the patients with a register-based diagnosis of ALS and 
MS/MG/IP/DMPM in Sweden, we showed that in most cases one of the two diseases had been 
misdiagnosed. This is a result that might not be specific to the Swedish diagnostic system. 
Hence, we recommend that researchers exercise caution when using register-based diagnosis 
to study the concurrence between these diseases. However, we do not aim to discredit the 
accuracy of the Swedish Patient Register, or register-based research for ALS in general, as the 
high percentage of misdiagnosis in our study is not an accurate representation of overall quality 
of ALS diagnoses in the Swedish Patient Register. We believe that this finding is specific to 
this particular and very small group of patients with unspecific symptoms at disease onset. 
Indeed, our research group previously validated the register-based diagnosis of ALS in the 
Stockholm county and found a positive predictive value of 91%, which extended to 97% when 
PLS was included in the definition of ALS19. 
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9.4 RITUXIMAB LOWERS THE RISK OF DEPRESSION IN RRMS 
By prospectively following a nationwide population-based cohort of RRMS patients, we 
showed that when patients were prescribed rituximab, the risk of depression or antidepressants 
prescription was lower compared to when patients were prescribed interferons. We did not find 
evidence for an effect of depression or antidepressants on DMT discontinuation, nor on MS 
relapse after DMT start.  
We are the first to identify an inverse association between rituximab and depression or 
antidepressants prescription in RRMS. We speculate that rituximab might act on inflammatory 
pathways related to depression, in addition to the inflammatory pathways of MS. It is also 
possible that patient satisfaction of rituximab, an effective drug with good tolerability profile 
and lower discontinuation than other DTMs204-207, might be one of the explanations for the 
observed lower risk of depression or antidepressants prescription.  
In contrast to previous research reporting an inverse association between depression and MS 
relapses208-210, we did not find an association between receiving a depression diagnosis or being 
prescribed antidepressants and DMT discontinuation or MS relapse. The fact that we excluded 
the TCAs and SNRIs from our definition of antidepressants might have explained to some 
extent such contrasting findings.  
9.5 STRENGTHS 
The findings discussed in this thesis are based on population-based nationwide studies with 
prospective design. We were able to conduct extensive follow-up on all study participants, with 
virtually no attrition (except in the rare case when individuals emigrated out of Sweden, which 
is believably non-differential). Therefore, with the exception of Study I (where we only 
investigated males), the findings should be generalizable to the entire Swedish population.  
All exposure variables were assessed independently of the later outcomes and are therefore not 
influenced by biases in relation to outcome status (such as recall bias). Moreover, all variables 
have satisfactory validity because they were assessed and validated by health professionals or 
systematically recorded by governmental agencies.  
Furthermore, we had the unique advantage of being able to objectively identify family 
members, as well as their disease diagnoses, making it possible to assess potential genetic and 
environmental contributions to the associations of interest. Overall, the large sample size of all 
studies allowed for sufficient statistical power in detecting effect sizes of smaller magnitudes, 
despite the low prevalence of ALS. We were also able to validate and study an extremely small 
subgroup of ALS patients that were concurrently diagnosed with other neuromuscular diseases, 
resulting in the largest study to date on the concurrence of ALS and MS/MG/IP/DMPM.  
9.6 LIMITATIONS 
Despite our efforts to account for all available confounding factors, we lacked information 
about life-style factors such as smoking and dietary habits. Hence, residual confounding 
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remains a possibility. Life-style factors might also have acted as mediators, and studying such 
pathways might have led to a greater understanding of the underlying mechanisms for some of 
the observations made in the thesis.  
We also lacked information about the genetic characteristics of the ALS patients identified. It 
was therefore not possible to examine if our findings are specific to sporadic ALS or ALS with 
known mutations. In Studies I and II, we were also unable to examine if our findings were 
applicable to ALS of different clinical subtypes. 
We might have underestimated the prevalence of some psychiatric disorders not requiring 
specialist care. For example, some patients with psychiatric disorders manifesting with less 
severe symptoms might not get referred by their general practitioner, or might choose not to 
engage with a specialist. Such individuals would not end up in the Swedish Patient Register. 
Hence, the results pertaining to psychiatric disorders might only be generalizable to the more 
severe forms of the disorders.  
When estimating the age-specific associations between physical and cognitive fitness and ALS, 
we did not have a sufficiently large number of ALS patients to gain adequate statistical power 
for each age band investigated. Therefore, caution is needed when interpreting the results in 
terms of specific ages at risk.  
We were not able to follow the children of ALS patients and ALS-free individuals long enough 
to reach the peak age for the diagnosis of neurodegenerative diseases. Hence, the analysis of 
risk of neurodegenerative diseases among children of ALS patients might have suffered from 
a so-called “right truncation effect” which would lead to an underestimation of the true 
estimate.  
It is possible that the reported differences in terms of ALS treatment between patients with only 
ALS, and patients with concurrent ALS and MS/MG/IP/DMPM, are due to a cohort effect. 
Nevertheless, most of the patients with concurrent diagnoses received the ALS diagnosis in 
1997 and thereafter, when the practice of non-invasive ventilation treatment was already 
common211, as well as treatment with riluzole212. We compared patients with concurrent ALS 
and MS/MG/IP/DMPM visited at hospitals from the entire Sweden to patients with only ALS 
attending hospitals of the Stockholm area. It is therefore possible that factors like SES or 
genetics might contribute to some of the observed differences.  
Surveillance bias might have played a role in the protective effect of rituximab treatment on 
the risk of depression or antidepressants prescription among RRMS patients. Because 
rituximab is administered twice a year as an infusion, whereas natalizumab is administered 
every month, a less frequent contact with healthcare staff might not have prompted the 
detection of depressive symptoms. On the other hand, in comparison to other DMTs such as 
fingolimod and dimethyl fumarate (which are taken orally) and interferons (which are self-
administered injections), rituximab requires more contacts with the clinics.  
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10 CONCLUSIONS 
In summary, based on collective evidence from the present thesis, we found evidence that 
neuroinflammation might precede the onset of ALS (Figure 13).  
In a small subgroup of ALS patients, motor neuron degeneration might be triggered by chronic 
or acute neuroinflammation around the motor unit (Study III).  
High level of physical fitness in young adulthood, possibly reflecting intense levels of physical 
activity and the resultant inflammatory status in proximity to the muscles, tendons, joints, and 
peripheral nerves, is associated with a higher risk of early onset ALS (Study I). 
Different neurodegenerative diseases and ALS might share common disease mechanisms 
including neuroinflammation, which might in part explain the increased risk of 
neurodegenerative diseases among ALS patient from years before ALS diagnosis (Study II). 
Neuroinflammation might also be a contributing factor to the increased risk of psychiatric 
disorders among ALS patients, in addition to a strong stress response to early symptoms of 
ALS and receiving the fatal diagnosis. The severe stress response to ALS diagnosis might also 
have contributed to the increased risk of psychiatric disorders observed among children of ALS 
patients (Study II). 
Treatment with rituximab might decrease the risk of depression and antidepressants 
prescription among RRMS patients. One potential explanation might be through modulating 
both the MS- and the depression-related inflammatory responses in RRMS (Study IV).   
 
Thesis hypotheses  
 
Figure 1. Schematic representation of the thesis hypotheses (reprinted for convenience).   
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Conclusions Study I 
 
 
Conclusions Study II 
 
 
Conclusions Study III 
 
 
Conclusions Study IV 
 
 
Figure 13. Schematic representation of the conclusions drawn from the results of the constituent papers of this 
thesis. Decomposed and adapted from the schematic representation of the thesis hypothesis depicted in Figure 1. 
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10.1 FUTURE RESEARCH AND CLINICAL IMPLICATIONS 
Because of intrinsic limitations of the studies of this thesis, further research is needed to 
continue exploring the role of neuroinflammation in ALS and MS and ultimately help to draw 
clinical recommendations. We recommend the following:  
1. Replicate all findings outside Sweden to test if these results are generalizable to other 
populations.  
2. Investigate if high level of physical activity in young adulthood predicts risk of ALS 
among females. It would also be interesting to investigate if physical fitness later in life 
also predicts ALS diagnosis. Should genetic prediction improve, it might be advisable 
to refrain from engaging in intense physical activity among individuals with high 
susceptibility of ALS.  
3. Pool together patients with concurrent ALS and MS/MG/IP/DMPM from different 
countries in order to obtain a sufficiently large sample size to examine if patients with 
such rare concurrences differ in terms of other important clinical characteristics. 
Studying potential differences in outcomes such as survival might eventually lead to 
further identification of therapeutic options.  
4. Conduct further studies to confirm the protective effect of rituximab on depression as 
well as on overall quality of life. If confirmed, it might be worthwhile to promote the 
psychological benefits of rituximab as effective DMT for RRMS patients.  
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